Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 10/20 | 0.56 |
| ▸ | CTSL | P07711 | 3/20 | 0.55 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.55 |
| ▸ | CTSH | P09668 | 1/20 | 0.55 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
| ▸ | MC5R | P33032 | 1/20 | 0.54 |
| ▸ | MC3R | P41968 | 1/20 | 0.54 |
| ▸ | MC1R | Q01726 | 1/20 | 0.54 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.53 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30258085 | 0.96 | CXCL8 (0.55) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL29845337 | 0.88 | CXCR4 (0.58) | CXCL8KISS1RCXCR4 | |
| SCHEMBL30218939 | 0.87 | CXCR4 (0.65) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL30317539 | 0.85 | KISS1R (0.55) | CTSLCTSSCTSKCTSHKISS1R | |
| SCHEMBL29845535 | 0.85 | CXCR4 (0.60) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL30512650 | 0.84 | CXCL8 (0.57) | CXCL8KISS1R | |
| SCHEMBL31452904 | 0.84 | CTSL (0.62) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL30797902 | 0.84 | CXCR4 (0.58) | CXCL8CTSLCTSSCTSKCTSH | |
| SCHEMBL30381557 | 0.84 | KISS1R (0.59) | CXCL8KISS1RCXCR4 | |
| SCHEMBL30293938 | 0.84 | TACR1 (0.65) | CXCL8CTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218815-A2 | USE OF ANTI IL-1BETA ANTIBODIES | Novartis AG (CH) | 2023-08-02 | — | — | EP | claimed |
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20260125463-A1 | Methods of Using IL-1beta Compounds | NOVARTIS AG (CH) | 2026-05-07 | — | — | US | disclosed |
| US-20240083997-A1 | Methods of Using IL-1beta Compounds | NOVARTIS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| EP-4218815-A2 | USE OF ANTI IL-1BETA ANTIBODIES | Novartis AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| EP-4177268-A2 | NEW INDICATIONS FOR ANTI-IL-1BETA THERAPY | Novartis AG (CH) | 2023-05-10 | — | — | EP | disclosed |
| EP-3332807-B1 | USE OF ANTI IL-1BETA ANTIBODIES | NOVARTIS AG (CH) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146083-A1 | Methods of Treating Kawasaki Disease Using IL-1beta Antibodies | IL1A, IL1R1, FCGR2A | CXCL8 533/4885CTSL 1571/4885CTSS 2229/4885 |
| US-20260125463-A1 | Methods of Using IL-1beta Compounds | IL1B, IL1RN, IL1A | CXCL8 225/4885CTSL 1383/4885CTSS 2072/4885 |
| US-20240083997-A1 | Methods of Using IL-1beta Compounds | IL1RN, IL1A, IL1B | CXCL8 42/4885CTSL 182/4885CTSS 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.